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Abstract 
Although the current doctrine of IBD pathogenesis proposes an interaction between 
environmental factors with gut microbiota in genetically-susceptible individuals, dietary 
exposures have attracted recent interest and are, at least in part, likely to explain the rapid rise in 
disease incidence and prevalence. The D-ECCO working group along with other ECCO experts 
with expertise in nutrition, microbiology, physiology and medicine reviewed the evidence 
investigating the role of diet and nutritional therapy in the onset, perpetuation and management 
of IBD. A narrative topical review is presented where evidence pertinent to the topic is 
summarized collectively under three main thematic domains: i) the role of diet as an 
environmental factor in IBD aetiology; ii) the role of diet as induction and maintenance therapy 
in IBD; and iii) assessment of nutritional status and supportive nutritional therapy in IBD. A 
summary of research gaps for each of these thematic domains is proposed which is anticipated to 
be agenda setting for future research in the area of diet and nutrition in IBD.  
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Introduction 
The current dogma of inflammatory bowel disease (IBD) pathogenesis involves a complex, yet 
elusive, interaction between environmental factors and the gut microbiota in people who are 
genetically predisposed. However, the rapid rise in global prevalence of both ulcerative colitis 
(UC) and Crohn’s disease (CD) cannot be attributed to human genetics alone 1. Evidence now 
proposes that while human genetics are important, they explain only a small fraction of the risk 
of developing the disease, with microbial determinants and other environmental exposures 
thought to be more important than genetic susceptibility 2. Among environmental factors, dietary 
influences have attracted the most interest, and are likely to significantly contribute to the rapid 
rise in disease epidemiology 3. There are several lines of evidence to suggest that diet is a key 
player in the onset, perpetuation and management of the disease: Epidemiological evidence 
associates certain dietary nutrients and components to increased risk of IBD, exclusive enteral 
nutrition (EEN) is the primary induction treatment of active paediatric CD and there is emerging 
evidence that exclusion diets could treat or prevent subsequent disease flare. As malnutrition is a 
frequent presenting symptom of IBD that fluctuates erratically during the course of the disease, 
assessment of malnutrition and supportive nutritional therapy are important aspects of the 
multidisciplinary management of patients with IBD 4.  
 In contrast to the efforts thus far to understand the genetic and microbial origins of IBD 
or the development of effective and side-effect free pharmacological treatments in IBD, there is 
currently very little research on the role of nutrition or diet in these areas. As the current doctrine 
of IBD pathogenesis proposes a complex interplay between dietary influences, genetics and 
environment in the aetiology of IBD, there is now a pressing need to review past and current 
research and identify gaps for future research. The aim of this topical review was to extensively 
review the literature on the role of diet and nutrition in the aetiology and management of IBD 
and set the agenda for future research. 
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Methodology 
A contributors’ group was assembled involving all members of the D-ECCO Working Group 
(https://www.ecco-ibd.eu/index.php/about-ecco/ecco-operational-board/d-ecco-wg.htmland) and 
competitive application for membership of a Topical Review Group launched by ECCO. 
Selection of contributors was based on their curriculum vitae, a personal supporting statement 
and ensuring equal representation of professions and countries, as dictated by ECCO instructions 
for topical reviews and advised by its Governing Board. Three main thematic areas were selected 
a priori and working groups and thematic leaders were assigned for each.  
 A thorough literature search was conducted using Medline and a combination of 
appropriate keywords and Boolean operators. Search was limited to articles published in English 
and focus was given to recent evidence published over the past 15 years and until January 2016. 
Draft reports produced by each contributor were reviewed by the thematic leaders and project 
coordinators. The main research gaps were identified and agreed by consensus in a face-to-face 
meeting involving all contributing authors in Amsterdam in March 2016. Consensus was defined 
as agreement of >80% following blind electronic voting and discussion between contributors 
where required. The final manuscript for publication was reviewed by all members of the 
Topical Review Group and approved by the Governing Board of ECCO. 
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1. Role of diet as an environmental factor in IBD aetiology 
1.1 Diet, Microbiota and Pathogenesis of IBD 
Diet can contribute to gastrointestinal health, either via direct effects on gut homeostasis and 
barrier function or indirectly via the intestinal microbiome (Supplementary Figure 1). This 
densely populated microbial community is shaped by host genetics and environmental factors, 
and comprises a limited number of phyla, dominated by Bacteroidetes and Firmicutes 5. It 
involves complex microbe-microbe and host-microbe interactions that vary along the 
gastrointestinal tract, with indispensable effects on host functions with regard to the immune 
system, epithelial and barrier function and its large metabolic capacity 6. Segregation into three 
robust clusters (i.e. ‘enterotypes’) driven by Bacteroides, Prevotella and Ruminococcus 7, is 
associated with long-term dietary preferences, (i.e. high protein and fat consumption with the 
Bacteroides and carbohydrate-rich diets with the Prevotella enterotype) 8. Others reported on a 
bimodal distribution in microbial gene richness, in which a lower richness was associated with 
impaired metabolic factors and inflammation 9 and being less responsive to dietary interventions 
10. 
 The global increasing incidence in IBD seems to be associated with western lifestyle 11,12. 
Diet can shape the microbiota composition and activity and impact host-microbe interactions. 
Dietary intake of a high protein diet and/or red meat can result in increased production of 
bacterial metabolites, such as ammonia, indoles, phenols and sulphide, that may be harmful to 
the gut 13. On the other hand, bacterial fermentation of non-digestible carbohydrates, results in 
short-chain fatty acids (SCFAs), which are an energy source for host epithelial cells and act as 
signaling molecules with anti-inflammatory, immunomodulatory, anti-oxidative and improved 
mucosal barrier effects 14. Fat can have effects on the microbiome by release and conversion of 
bile salts 15 and altering the microbiota composition 16.  
 However, it is critical to appreciate the limitations of this rapidly expanding research area 
17. Common to all microbiome studies is the inherent variability (intra- and inter-individual) and 
the fact that even minor variations in research and laboratory methodology dramatically impact 
findings; this includes sampling, storage, DNA extraction, amplification, sequencing protocols, 
and data analysis 18,19. Disease factors (location, activity, medication, and faecal consistency) 
also impact the microbiome 20,21 and are often not taken into account. Most importantly, even 
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clear associations between microbes and IBD do not establish cause and effect 20,22. Therefore, 
interpretation of findings requires caution and findings may not always be reproducible. 
Nevertheless, there are several emerging specificities regarding the microbiome in IBD: 
Diversity: The single most reproducible finding of studies on microbes in IBD is a reduction in 
α-diversity. Diversity is generally thought to represent community health; reduced diversity 
results in less flexibility and adaptation and is likely to impact negatively on the microbial 
functional capacity. Reduced diversity can be the result of taxa elimination and/or bloom of taxa 
that displace others. Both are likely to occur in IBD 23. Reduced diversity as a marker of IBD 
could indicate pathogenic mechanisms; however, it also has prognostic value since reduced 
richness (representing number of species) predicts failure to respond to corticosteroids in 
children with severe UC 24. Recently, a reduction in the diversity of mucosa-associated bacteria 
was found in paediatric UC at non-inflamed sites, suggesting that the microbial changes may be 
an inherent defect in IBD and not just the result of inflammation 25. 
Compositional changes: For the reasons stated above, it is difficult to commit to specific 
reproducible alterations in microbiota in IBD. Frequent phylum-level observations include 
reduction in Firmicutes and Bacteroidetes and an increase in Proteobacteria 26. 
Enterobacteriaceae are frequently increased in IBD, and are especially relevant since they 
include Escherichia coli (such as adherent-invasive strains) 27. Rodent models of colitis have 
demonstrated that colonisation with adherent-invasive E. coli (AIEC) may be affected by diet 28. 
Other taxonomic groups are depleted in IBD, such as Clostridia, Ruminococcaceae, and 
Bifidobacteria, and at species level, many have reported losses of Faecalibacterium prausnitzii, 
which may also have functional roles 22,29. Beyond the identity of bacteria, one must also 
consider their spatial organization, which is altered in IBD 30. Some of the observed changes are 
mediated by access to nutrients and oxygen gradients 31. 
Functional changes: Current focus is shifting towards the functional capacity of the microbiome, 
as ‘what are they doing’ might be more important than ‘who is there’. The European MetaHIT 
Project identified a functional microbial dysbiosis in patients with IBD 32, supported also by 
others 33. Metabolomic analyses of breath or faeces revealed differences in IBD versus controls, 
(e.g. reduced butyrate, acetate, and (tri)methylamine and elevated amino acid levels) 34-36. 
Interestingly, individuals with UC appear to have defective or deficient production of SCFA 37,38. 
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Furthermore, analysis of microbiota-derived small molecules, considered important mediators in 
microbe-microbe and microbe-host interactions, reveal a variety of biological actions, including 
antibiosis and immune modulation 39. Further studies integrating the metagenome with proteome 
and/or metabolome data in IBD, and taking into account disease phenotypes, activity and 
medication use, are needed.  
 The observed microbial perturbations can result from the disease itself, but may also 
contribute to inflammation as shown by transfer of microbiota from colitis models to wildtype 
donors 40,41 and improvement of disease activity after decontamination of the gut lumen 42,43. So 
far, microbial modulation of disease activity by administration of probiotics or prebiotics showed 
limited efficacy 44. However, findings, mainly resulting from metabolic and animal studies, 
clearly demonstrate that diet can impact gut homeostasis and immune function via the 
microbiome.  
 
Research gaps: 
 Establishing causality between diet, microbiome and IBD is an important research gap. 
Priority should be given to a systems biology approach. 
 Longitudinal studies investigating early life exposure including diet, microbiome, and 
other environmental factors on IBD onset are needed. 
 Stratification of patients by disease phenotype, specific microbial perturbations and dietary 
intake will be necessary to develop successful therapeutic and/or preventive strategies. 
 Studies evaluating the ability to modify the microbiota by dietary interventions, and the 
effect on disease in affected individuals should be a priority. 
 
1.2 Effect of Diet on Rodent Models and Cell Lines 
Multiple dietary components have been shown to cause or aggravate inflammation in animal 
models of IBD 20,28,45-47. Due to the concise nature of this review, we will confine ourselves to 
landmark studies that demonstrate an association between dietary components and inflammation 
in IBD models, or those studies that best highlight research gaps.  
 Key dietary components thought to be possibly associated with CD in animal models and 
cell lines include high fat (HF), high animal or milk fat, or high fat/high sugar (HF/HS) diets 
20,28,45,46, as well as gluten 47, maltodextrin 48, emulsifiers 49-51 titanium dioxide nanoparticles 52, 
luminal iron 53 and aluminum a food chain contaminant 54.  
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 All of these are common components of diets in economically-developed countries, so-
called ‘Western diets’. Martinez-Medina et al 28 used a transgenic CEABAC10 mouse that 
uniquely expresses CEACAM6, the ligand for CD-associated bacteria AIEC, to compare the 
effect of standard chow to HF/HS ‘Western diet’ and AIEC infection.  Both wild type and 
transgenic mice fed a HF/HS diet were more likely to develop dysbiosis, increased intestinal 
permeability, decreased expression of mucins and mucus thickening. In addition, CEABAC10 
mice fed HF/HS were rapidly colonized by AIEC and presented higher degree of crypt abscesses 
when compared to the standard chow group. Another study highlighting the role of specific fats, 
namely isocaloric low fat (LF), polyunsaturated fatty acids (PUFA) and milk-derived fat (MF), 
in IL-10-/- mice was conducted by Devkota and colleagues 20. They reported an increase in colitis 
severity in the MF group compared to PUFA- and LF-fed IL-10-/- mice. Colitis was also 
associated with the bloom of colitogenic Bilophila wadsworthia in the MF group, and was 
dependent of exposure to MF-induced taurine conjugated bile acids. Sodium caprate in MF has 
been shown to increase intestinal permeability independent of the taurine dependent mechanism 
previously described 20. High fat was also shown to accelerate ileitis in a TNF∆ARE/WT mouse 
model 45. The same group subsequently demonstrated that gluten induced ileitis in these mice 
through the gluten-dependent increased intestinal permeability 47. 
 Adherence of AIEC via CEACAM6 appears to be critical for the pathogenic effect of this 
strain in human CD. Maltodextrin, a key polysaccharide used in sweeteners (Sucralose) and as a 
thickening agent was shown to enable AIEC adherence and biofilm formation independently of 
the presence of CEACAM6. In a viewpoint article, Roberts and colleagues hypothesised that the 
increased incidence of CD could be attributed to a higher consumption of emulsifiers in 
processed foods 55. In support of this hypothesis, Chassaing and colleagues 48 showed that TLR5-
/- and IL-10-/- mice exposed to two common emulsifiers, carboxymethylcellulose and 
polysorbate-80, develop obesity/metabolic syndrome in TLR5-/- and severe colitis in IL-10-/-. 
Both mice strains fed the emulsifiers showed increased gut permeability, reduced mucus 
thickness, higher penetration of intestinal bacteria and dysbiosis. These changes resulted in an 
accelerated metabolic syndrome in TLR5-/- mice and in an increased incidence and extent of 
colitis and enrichment in Bilophila spp. in IL-10-/- mice with both CMC and polysorbate-80. In 
line with these results, translocation of E. coli across M-cells was increased in the presence of 
polysorbate-80 50.  
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 The studies outlined above accentuate the aggravating effect of HF diets in models of 
CD, however, the results to date on the effect of HF on disease in animal models of UC are 
inconclusive 56-59. The reason being differences in diet composition (e.g. fat/sugar ratio, n-3/n-6 
ratio), duration of diet consumption and type of model used. For example, HF or n-6 PUFA 
feeding to mice exposed to Dextran Sodium Sulphate (DSS)-induced colitis resulted in either 
worsening or amelioration of disease 56,57,59. In contrast, HF feeding to Mdr1-/-, a spontaneous 
model of UC, led to worsening of colitis, although no colitis was observed in WT mice 58.  
 An exciting new concept involves "humanised mice" which may contain human genes or 
microbiome. Studies involving diet with such models could shed more light on the interaction 
between diet, microbiome and IBD in humans. An important research gap is the development of 
a model in which different food ingredients could be tested with relevance to the human 
condition.  
 In conclusion, the collected data points towards diet-induced effects on microbiota 
composition, epithelial responses and inflammation primarily in genetic susceptible animals but 
less in wild type animals. The translational relevance of these findings to the human conditions is 
yet to be addressed.  
 
Research gaps: 
 Studies should evaluate if improvement of intestinal inflammation can be achieved 
with dietary interventions in animal models 
 Development of experimental models as a platform for testing multiple dietary 
ingredients potential to cause or inhibit inflammation should be a priority. 
 
1.3 Epidemiology Linking Diet with risk of IBD  
Epidemiological evidence shows that individuals migrating from regions of low IBD prevalence 
to higher-prevalent regions are at increased risk of developing IBD 60. Numerous studies have 
evaluated the association between pre-illness intake of specific nutrients such as fats, 
carbohydrates and protein and food groups such as fruits, vegetables and meats for UC. All were 
case–control studies and analysed dietary intake retrospectively. The most frequently reported 
food components associated with IBD were cereals, fibre-containing food, bread, sugar and 
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sugar-containing foods, fruits and vegetables, fat, sucrose, starch or total carbohydrate and 
protein intake or energy drinks 14,61-64.  
Despite methodological limitations, several prospective studies have consistently 
identified animal protein to be associated with increased risk of UC 61,64,65. In the study by 
Jantchou et al, the highest tertile for consumption of animal protein had a hazard ratio of 3.29 for 
developing UC (p=0.005). Jowett et al. studied 191 UC patients, and they demonstrated a 
significant association between high meat intake and risk of relapse of UC 65.  
 Although several studies suggested significant associations of particular dietary habits in 
UC 14, an equal or even higher number of studies could not confirm these findings. Since many 
of the current methodologies are based on historical food frequency questionnaires (FFQ) the 
current evidence is not sufficient to draw firm conclusions on the role of specific nutrients in the 
aetiology of UC. Dietary ingredients in western diet are not limited to the "natural components" 
listed above. There is an increased consumption of food additives, such as sweeteners, 
emulsifiers, thickeners, preservatives and food colorings. These products, some of which have 
been linked to IBD 49,62,66, should be further investigated in large well-designed epidemiological 
studies that provide data regarding exposure to these products.  
 The Nurses’ Health Study examined the association between fibre intake and incident 
IBD. Subjects consuming large amounts of fibre, particularly fruits, were less likely to be 
subsequently diagnosed with CD, although no association was observed for UC 67. There is 
evidence for a gene–diet interaction, in which variants in genes for fatty acid metabolism affect 
the relationship between IBD risk and PUFA consumption 68. Together, these findings support 
the hypothesis that consumption of fruits and possibly vegetables, rather than meats and fats, can 
lower the risk of IBD. The study using the European Prospective Investigation into Cancer and 
Nutrition (EPIC) database prospectively investigated the impact of nutrition on IBD 
development 69. The EPIC-IBD study is a sub-cohort involving a total of 401,326 initially 
healthy men between 1991-1998. In this large multicenter prospective study using dietary data 
from a validated FFQ, they did not find any associations between total dietary carbohydrate, 
sugars (monosaccharides and disaccharides), or starch intakes and the odds of developing CD 
and UC. D’Souza et al assessed Canadian children for dietary patterns, and idenified a diet rich 
in fruit and vegetables (prudent diet) as protective for CD while a partial ‘Western diet’ 
increased risk for CD 70. 
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Research gaps: 
 Risk associated with consumption of commercially processed food, including, but not 
limited to nutrients, additives and processing should be assessed in longitudinal studies 
 Future studies should address dietary patterns rather than individual dietary components   
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2. Diet as induction and maintenance therapy in IBD 
2.1Exclusive Enteral Nutrition in Management of IBD  
Exclusive enteral nutrition is the most extensively researched dietary intervention for induction 
of remission in mild to moderate CD both in children and adults. Case series and clinical trials 
have demonstrated the ability of EEN to induce clinical remission in approximately 80% of 
patients. Treatment response rates varied depending upon type of study design (retrospective or 
prospective), type of analysis (per protocol or intention to treat) 71-73, but seem to be independent 
of type of formula and its constituent nutrients. 
 In paediatrics, a meta-analysis of studies comparing EEN to standard treatment has 
demonstrated an overall combined remission rate for EEN of 73% 74, whereas two large, single-
center studies have confirmed a treatment efficacy of approximately 80% 71,73. Similar remission 
rates were reported in studies conducted in adults, particularly one randomised controlled study 
demonstrated that 21/30 adults refractory to steroids entered remission with EEN 75,76.  However, 
the most recent meta-analysis demonstrated that steroids were more effective than EEN 77.  
Studies on EN in adults are sparse, of poor quality and therefore it is difficult to draw clear 
conclusions. Interestingly, and in contrast to steroids effect, EEN also has the potential to induce 
mucosal healing. In a prospective Australian study, 58% of patients had early endoscopic 
response, and one third had complete transmural healing on small bowel imaging 78.   
 Disease severity and luminal disease seem to be the only significant predictors of 
response to EEN 69,70. According to the ECCO/ESPGHAN consensus, EEN should be the first 
line therapy to induce remission in children with active mild-to-moderate luminal CD 79.  There 
are no data supporting the use of EEN for extra-intestinal manifestations or penetrating disease.  
 It has traditionally been speculated that use of EEN should be limited to patients with 
small bowel involvement, however results from further meta-analyses have shown no difference 
in the efficacy of EEN when considering disease location 73,74,80. Likewise, there are no 
confirmatory data on the effectiveness of such treatment in severe isolated Crohn's pancolitis, 
and no data for isolated oral or perianal disease. 
 The efficacy of EEN has been attributed to different mechanisms including bowel rest, 
anti-inflammatory effects, restoration of the epithelial barrier and favorable changes in the 
intestinal microbiota 81. As both polymeric and elemental formulas show similar efficiency 76,82, 
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gut rest is unlikely to be the primary mechanism. More recently, the effect of EEN has also been 
related to the exclusion of specific components from the diet 83. 
 A few studies have demonstrated a decrease in pro-inflammatory 84 and an increase in 
anti-inflammatory molecules (TGF-β) 85 in response to EEN. Incubation of CD-biopsies with 
elemental formula led to an increased ratio of IL-1Ra to IL-1 β compared to control samples 86. 
Other authors confirmed the direct effect of a polymeric formula on colonic epithelial cell 
chemokine responses to the pro-inflammatory cytokine TNF-α 87. At the mesenteric fat level, 
EEN treatment decreased pro-inflammatory adipokines (TNF-α and leptin) and increased 
adiponectin levels 88.  
 The effects of EEN on the intestinal barrier have mostly been clarified by in vitro or 
animal studies. In human colonic epithelial cells, EEN has been found to prevent epithelial 
barrier dysfunction in the presence of TNF-α 89. In IL-10-/- mouse model of colitis, EEN 
treatment maintained normal gut barrier function and integrity and reversed inflammatory 
changes 90. 
 Profound changes in the composition of mucosal microbiome induced by EEN have been 
suggested by pioneer investigations 91 and recently confirmed by several studies. Reduced 
diversity of the microbiota, occurring after a few days or weeks of EEN, has been frequently 
reported 92-95. The microbiome effect induced by EEN differs from the one induced by anti-TNF 
medications and most importantly from partial EN (PEN) 96. In contrast, one study demonstrated 
an increase in species diversity after elemental diet 97.  Species specific effects induced by EEN 
were reported by different authors, particularly a significant decrease in Bacteroides 92-94,98. A 
reduction of F. prausnitzii was observed both in adults 99 and children 92, challenging the 
previous paradigm of a protective role in CD. Reports describing changes in the intestinal 
metabolic profile are unequivocal 92,100. A single study reported the metagenomic changes 
induced by EEN, particularly an increase in relative abundance of genes involved in cell growth 
and renewal and possibly in tissue healing 95.  
 The efficacy of EEN related to the exclusion of some dietary components is indirectly 
supported by studies indicating that PEN associated with a normal diet did not induce remission 
72, while 70% of children and 69% of adults on a PEN combined with a specific CD exclusion 
diet achieved remission 83. Furthermore, specific dietary restriction seems to be therapeutic in 
CD 101,102.  
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 There are not enough studies to determine the optimal duration of EEN; the reported 
duration of an induction therapy varied from 2 to 12 weeks in studies, however it is most 
frequently used for 6 to 8 weeks. If the clinical response is not achieved within 3 weeks an 
alternative treatment should be considered. There is a paucity of evidence to guide the 
reintroduction of normal food after the end of EEN. There are few studies that have evaluated 
reintroduction of foods. Faiman et al demonstrated that rapid food reintroduction (3 days) after 
EEN is as equally effective as delayed food reintroduction (5 weeks) after follow up of 1 year 103. 
 
Research gaps 
 Mechanisms of action of EEN need to be explored, including the interaction of epigenetic, 
immunological and microbiological changes. 
 Studies evaluating the reintroduction of specific foods following EEN need to be 
performed 
 EEN should be evaluated in a variety of conditions, including adults with CD, in UC, 
complicated CD, and pre- and post-operative setting. 
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2.2 Partial Enteral Nutrition in Management of IBD 
Partial enteral nutrition (PEN) is the use of liquid enteral formula in addition to consuming food 
for maintenance of remission or treatment of active CD; using <100% of total energy 
requirements from liquid nutrition. There is increasing interest in the use of PEN (Supplementary 
Table 1). In part, as a result of the limitations of EEN, with food abstinence and the monotony of 
drinking enteral formula being common reasons for poor compliance to and subsequent success 
of EEN 104. The mechanisms via which PEN might impact on CD activity, if at all, are poorly 
understood. Unlike EEN, the complete removal of dietary antigen as a hypothetical mechanism 
is no longer the case, therefore if studies indicate that PEN is at least as effective as EEN then 
this might also exclude this as a mechanism for the effectiveness of EEN. 
 Type of supplementation varies widely between studies and clinical practice 72,83,105-110. 
The volume investigated has ranged from 35-90% of total energy requirements and the food 
consumed can either be a free diet or a defined restrictive diet. A small number of studies have 
investigated PEN compared to normal diet for maintenance of remission 105,106,109-112. One RCT 
evaluated PEN with normal diet for the maintenance of adults with recently-induced remission of 
CD 106. The study was halted early due to an interim analysis showing improved outcome in 
those following PEN. The relapse rates in the PEN arm (35%) were lower compared with normal 
diet (64%), with a multivariate adjusted hazard ratio for relapse of 0.40 106. 
 Another RCT compared PEN (≥900 kcal/day) with 6-mercaptopurine (6-MP) and to no 
drug therapy (normal diet, no placebo) 105. At 2 years, PEN resulted in 56% relapse, 6-MP in 
43% (no difference) but both were lower than control normal diet (79%). 
 Several non-randomised trials have investigated the effect of PEN on maintenance of 
remission; a selection of key studies is presented here (Supplementary Table 1). In another study, 
patients in medically-induced remission were selected to continue to have PEN plus low fat diet 
(if they had previously been compliant to EEN) or to follow normal diet (if they had previously 
been non-compliant to EEN) 109. At 12-months, PEN resulted in lower relapse rates, lower 
disease activity and lower endoscopic inflammation compared with normal diet. In an identical 
study published by the same group but in those with surgically-induced remission, PEN was 
confirmed to lower relapse rates and endoscopic recurrence compared with normal diet at 12 
months 110, whereas in those with infliximab-induced remission it was not shown to impact 
relapse rates 113. Finally a retrospective, non-randomised trial in children with EEN-induced 
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remission, compared relapse rates in those who chose to continue nocturnal PEN compared with 
those who did not 112. PEN reduced relapse rate at both 6 months and 12 months.  
 There is only one RCT of PEN in the treatment of active CD in comparison with normal 
diet. This was a randomised, cross-over trial in adults with on average very mildly active CD and 
malnutrition 114. Although some nutritional markers were improved, PEN did not impact on 
disease activity (Harvey Bradshaw Index) 114. One RCT has compared elemental PEN and EEN 
for induction of remission in children with moderate to severely active disease over a six-week 
period. However, PEN resulted in fewer patients entering remission and a smaller reduction in 
PCDAI compared with EEN 72.  
 A recent, non-randomised trial compared PEN with EEN or anti-TNF treatment for the 
treatment of active CD in children/adolescents, with patients allocated to the intervention based 
upon the unit in which they were recruited 115. Following 8-weeks, fewer patients receiving PEN 
had a clinical response compared with either EEN or with anti-TNF treatment and fewer were in 
clinical remission. However, the limitation of non-randomised treatment allocation and clinically 
important differences in baseline characteristics makes interpretation of these findings difficult 
115. One uncontrolled trial has investigated PEN in conjunction with a CD exclusion diet in 
children/young adults, reporting a clinical response in 78.7% and with 70.2% entering full 
disease remission 83. 
 
Research gaps 
 Investigation of the effectiveness of PEN as a monotherapy or in combination with 
medical therapy for preventing relapse in IBD is a research gap 
 The optimal regimen of PEN for maintenance of CD, including the dose, composition, 
duration, method of delivery of feeding, and nature of the accompanying oral diet should 
be identified. 
 
 
2.3 Elimination Diets in Management of IBD  
EEN is an effective therapy for induction of remission in CD 74; however there are drawbacks. 
EEN is difficult to adhere to, particularly in adults 104, and there is limited evidence for post-EEN 
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strategy. Understanding the mechanism of response could lead to diets that are easier to comply 
and follow that could be implemented for longer duration. 
 Several elimination diets have been developed and evaluated for induction of remission, 
maintenance of remission or improvement of functional symptoms (Supplementary Table 2). 
This field still lacks adequately powered high quality studies. Most of the published data have 
severe methodological limitations or did not report standardised clinical outcomes such as 
remission, decline in inflammation or mucosal healing.  
 Diets reviewed included the Specific Carbohydrate Diet (SCD) 116, the Crohn's Disease 
Exclusion Diet (CDED) 83, the Anti-inflammatory diet (IBD-AID) 117, Allergen elimination diet 
(IgG) 118, the Semi-vegetarian diet (SVD) 119, the low Fermentable Oligo-saccharides, Di-
saccharides, Mono-saccharides And Polyols diet (FODMAP) 120,121, and the Mediterranean Diet 
122. Only one study for UC met requirements for outcomes 123. A summary of these diets is 
presented in Supplementary Table 2. However, only two diets (SCD and CDED) reported 
significant improvement in clinical remission and data demonstrating a significant reduction in 
inflammation and therefore are discussed here. 
 The theoretical assumption underlying the SCD is that CD is caused by malabsorption of 
disaccharides and complex carbohydrates resulting in bacterial overgrowth and intestinal injury 
124. Cohen et al 116 conducted a prospective pediatric study in 9 children with active CD using the 
SCD. Patients were evaluated using the PCDAI, Harvey-Bradshaw Index (HBI), and Lewis score 
at baseline, week 12 and week 52. At week 12, 6/10 entered remission (PCDAI<10) and 8/10 
showed significant mucosal improvement (P=0.012) compared with baseline. The Lewis score 
declined significantly from 2153±732 to 960±433 (P=0.012). Three patients had scores 
consistent with mucosal healing. Seven patients continued the diet up to 52 weeks, by which 
point the HBI (0.1 ± 0.4) and PCDAI (5.4 ±_5.5) remained low (P = 0.016 and 0.027 compared 
to baseline), with 2 patients showed sustained mucosal healing. Obih et al 101 conducted a 
retrospective study with the SCD in 26 patients (20 CD, 6 UC). They demonstrated an 
improvement in the abbreviated PCDAI during 12 months, however several patients received 
additional induction medication while others started the diet while being in remission. Walters et 
al 125 evaluated the composition and complexity of the gut microbiota and resolution of IBD 
symptoms between the SCD and a Low Residue Diet. They demonstrated a general increase in 
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the microbial diversity of faecal samples under the SCD and decrease in diversity among the 
Low Residue Diet.   
  The Crohn’s Disease Exclusion Diet (CDED) is based on exclusion of dietary 
components that in rodent models have been demonstrated to impair innate immunity, increase 
intestinal permeability, cause microbial dysbiosis or allow bacteria to adhere and translocate 
through the intestine epithelium. The diet is rich in fibre and natural sources of resistant starch. 
Sigall Boneh et al 83 conducted a retrospective study to demonstrate their experience in 47 
children and young adults with active CD treated for 12 weeks.  Patients were reviewed at 
baseline, week 6 and week 12 and were evaluated with PCDAI, HBI, CRP, ESR, and albumin at 
each point. The diet was coupled with Partial Enteral Nutrition up to 50% of the energy 
requirements in most cases.  After 6 weeks, clinical remission was achieved in 33/47 patients 
(70%). Six out of seven (85.7%) patients who used the diet without supplemental formula, 
entered remission. Normalization of CRP was obtained in 21/30 (70%) patients with previously 
elevated CRP. At last follow-up, 11/15 patients evaluated had complete mucosal healing. This 
diet is currently being evaluated in two prospective randomised controlled trials. 
 Chiba et al conducted a prospective two year trial to evaluate the effect of a semi-
vegetarian diet in maintenance of remission in 22 adult patients in medical remission, with the 
control group comprising only 6 patients on regular diet. After 2 years of follow up, 16/22 
patients continued the semi-vegetarian diet and 15/16 maintained remission compared to 2/6 in 
the control group (p=0.0003) 119. 
 The original rationale for the low FODMAP diet in IBD was that several dietary 
FODMAPs may undergo fermentation that may cause tissue injury as a result of increased 
intestinal permeability 126. The use of FODMAP diet to manage functional symptoms in patients 
with IBD will be discussed later in this topical review.  
In conclusion, dietary manipulation offers promise for IBD, however there is an urgent 
need for RCTs to evaluate the efficacy of those diets together with their effect on the microbiota. 
 
Research gaps 
 Clinical trials to develop and evaluate efficacy of elimination diets for induction and 
maintenance of remission in IBD are required 
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 Dietary ingredients added or eliminated that are responsible for the clinical effects, and 
definition of mechanisms underlying response need to be identified. 
 
3. Assessment of nutritional status and supportive nutritional 
therapy in IBD 
Malnutrition is an extra-intestinal manifestation of IBD comprising undernutrition and 
overnutrition. It presents with different forms via a range of mechanisms and its severity varies 
during the natural course of IBD (Supplementary Figure 2). The origin and manifestations of 
undernutrition in IBD are multifactorial including suboptimal nutritional intake, alterations in 
energy/nutrient requirements and metabolism, malabsorption, excessive gastrointestinal losses 
and medication 4. While literature is still inconclusive, a higher basal metabolic rate:FFM ratio 
has regularly been reported in IBD patients compared with healthy controls 127-129 and children 
with CD fail to adapt their resting energy expenditure (REE) per kg lean mass to the same extent 
that patients with anorexia do 127. In adult CD patients, malabsorption is a major contributor to 
being underweight when in remission 130 and impaired gastric acid and pancreatic enzyme 
secretion were observed in undernourished patients 131. The effect of proinflammatory cytokines 
on energy/nutrient requirements, bone and development can also interact independently in the 
aetiology of undernutrition 132. Physical activity as contributor of total energy expenditure has 
barely been studied 133. Hence, assessment of nutritional status, prevention and correction of 
deficits is imperative and the cornerstone to multidisciplinary management of IBD patients. 
   
3.1 Assessment of Nutritional Status  
Involuntary weight loss and being underweight are common features of the newly diagnosed 
IBD patient and frequently accompany episodes of disease relapse. Whilst more common in CD 
than UC, presenting in approximately 60% and 35% of new cases respectively 4, recent evidence 
suggests that fewer patients currently present underweight, reflecting either the obesity epidemic 
or earlier disease recognition 134,135. There are limited data on the progression of undernutrition 
following diagnosis and whether this is predictive of disease outcomes. In a paediatric study, a 
similar proportion of children with CD had short stature two years post-diagnosis but being 
underweight decreased dramatically from 35% to 2% 134.  
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 IBD-specific alterations in body composition, with depletion of lean mass and normal or 
increased fat mass have been consistently reported 136. Hence, a high degree of adiposity and less 
lean mass should be expected for a given BMI. Interestingly, normalisation of BMI at two years 
follow-up has not been associated with an increment in fat-free mass (FFM) in CD 137, which 
suggests that BMI changes may not be good proxies for body composition changes in IBD. Such 
features of sarcopenia might be clinically relevant as people with IBD may have an increased 
risk of cardiovascular events 138 and recently intra-abdominal body composition has been 
associated with adverse clinical outcomes but both of these findings need to be replicated in 
prospective studies 139,140. 
 Osteopenia and osteoporosis are often seen in CD. Adult patients have a 60–70% higher 
risk for vertebral and hip fracture incidence compared with healthy controls 59,141. In children, 
data are not suggestive of increased fracture risk during childhood but it might be that a higher 
risk of fracture occurs early in adulthood. Up to 25% of CD patients will present with growth 
deficits, and a proportion will not attain their height predicted by genetic potential 142. 
 While clinical presentation of frank micronutrient deficiencies in IBD is rare and largely 
limited to case reports, low circulating levels are reported for most of micronutrients 4,143. 
However, caution should be paid in the interpretation of plasma micronutrient measurements in 
the presence of systemic inflammatory response (e.g. high CRP). Plasma concentrations of 
various micronutrients (e.g. iron, zinc, selenium, copper, vitamins A, C and E) are substantially 
affected by nutrient carrier protein concentration changes 144-146 so are unlikely to reflect total 
body reserves and inappropriate clinical interpretation may trigger unnecessary interventions 147. 
Development of novel biomarkers of micronutrient body stores are required and dietary intake 
assessment should complement biochemical indices.   
 In contrast to the wealth of data on clinical diagnostics and pharmacological management 
of IBD, limited data have explored the frequency of routine nutritional assessment and 
management of IBD, particularly in elderly patients where data are scarce. Data from a United 
Kingdom survey identified adult service resource gaps/shortages and absence of uniform practice 
standards on nutritional assessment and management 104. Assessment of nutritional status 
requires at least measurement and interpretation of anthropometry and dietary intake, making 
dietitians integral members of the multi-disciplinary team caring for patients with IBD 148. 
Assessment of body composition using sophisticated techniques is appealing, but the 
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implications of this for clinical practice improvement and patient benefit need to be explored and 
justify the resources used.  
 
Research gaps 
 There are limited data on the evolution of malnutrition following diagnosis and whether 
this is predictive of disease outcomes. 
 New biomarkers of micronutrient status are needed to overcome limitations of plasma 
measurements in the presence of systemic inflammatory response. 
 More research is needed on nutritional status and management of IBD patients, 
particularly in pregnancy, the elderly and pre-operative state. 
 
3.2 Supportive therapy in Short Bowel Syndrome in IBD 
Short bowel syndrome (SBS) is a rare but devastating complication of IBD characterised by 
malabsorption, typically following extensive or repeated intestinal resection. It is a form of 
(temporary) intestinal failure or intestinal insufficiency compromising fluid, electrolyte, and 
nutrient malabsorption leading to dependency of intravenous supplementation required for 
growth and health maintenance (e.g. in high-output (ileal) stoma or enterocutaneous fistula) 149-
151. Retrospective case-control studies report that early onset, family history of IBD, stricturing 
disease, younger age at first surgery, surgical complications and delay in diagnosis predispose 
towards SBS and intestinal failure in IBD 152-156.  
 Since SBS is accompanied by reduced intestinal surface, a biomarker is needed to 
diagnose clinically significant reduced intestinal mass/ intestinal function and monitor adaptation 
and mucosal healing. Potential biomarkers are serum citrulline (generation test) and intestinal 
fatty acid binding protein (I-FABP) 157-159. Studies on biomarkers that can predict or diagnose the 
presence of intestinal failure/intestinal insufficiency are required. 
 Glucagon-like peptide-2 (GLP-2; Teduglutide) enhances structural adaptation of the 
small intestinal mucosa in patients with SBS 160-162. Studies are lacking on the reparative 
(adaptation, mucosal healing) and immunomodulatory effects of GLP-2 in IBD patients with 
SBS. 
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 Intestinal transplantation may be considered in intestinal failure as a high-risk, last option 
treatment. A prospective study in 20 CD patients with chronic intestinal failure who were 
dependent on parenteral nutrition (PN) suggested that a scoring system enables the physician to 
identify which patients may benefit from intestinal transplantation before PN-associated 
secondary organ failure develops 163. Further work assessing which CD patients with intestinal 
failure receiving PN will benefit from intestinal transplantation are necessary to improve clinical 
and patient outcomes. 
 Enterocutaneous fistula can often be a serious complication of CD. Aggressive nutritional 
support to treat sepsis and reverse catabolic state can improve outcome 164.  Enteral nutrition for 
three months is an effective therapeutic strategy 165 and can prevent enterocutaneous fistula post-
operatively in CD 166. PN can also have a supportive role where enteral nutrition is 
compromised, but evidence is lacking on the efficacy to heal enterocutaneous fistula and other 
complicated fistulas in CD patients 167. Whether EN or PN is a more effective nutritional strategy 
in patients with fistulizing CD needs to be further elucidated.  
 High-output stomas in CD are common within three weeks of ileostomy and resolve 
spontaneously in almost half of patients, while the remaining need ongoing treatment due to a 
short small-intestinal remnant. Successful treatments include hypotonic fluid restriction, oral 
rehydration solution, salt rich diets, exclusive enteral nutrition and/or short-term parenteral 
electrolytes 168-171. Prospective research on optimal nutritional strategies to manage high-output 
stomas in IBD preventing dehydration and avoiding acute hospital admission (e.g. hypotonic 
fluid restrictions, and/or oral rehydration solutions, iv-glucose-sodium) should be compared with 
‘free diet’. Patient reported outcomes (e.g. quality of life) should also be considered. 
 Multiple factors relating to clinical, social, and economic issues contribute to lower 
quality of life (QOL) in patients dependent upon home PN172. Living with CD and intestinal 
failure reduces QOL and hugely impacts day-to-day living and inhibits autonomy 173, however 
there is limited research on QOL in CD patients with SBS. 
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 Multidisciplinary team working is crucial for optimising the management of 
SBS/intestinal failure in IBD 174. The value of the dietitian is important where available, however 
when not available, it is unknown whether there are failings in clinical and patient outcomes.  
 
Research gaps 
 New biomarkers that can predict, diagnose, monitor intestinal failure or intestinal 
insufficiency are needed in IBD 
 Nutritional treatment strategies for the management of high output stoma and intestinal 
failure/insufficiency in IBD need to be developed 
 
3.3 Supportive nutritonal therapy for functional bowel symptoms in 
IBD 
Functional bowel symptoms include abdominal pain, bloating, increased flatulence, diarrhoea 
and/or constipation and affect 35% of patients with inactive IBD 175; however, these symptoms 
can be mistaken for active IBD. Patients with IBD and coexisting functional bowel symptoms 
also exhibit increased anxiety/depression and reduced QOL compared with patients without 176. 
Clinical (symptoms) and objective (histological and inflammatory markers (e.g. faecal 
calprotectin, CRP)) assessment helps to distinguish between functional bowel symptoms and 
active IBD, although often the diagnostic validity is poor 177,178. Identification of functional 
bowel symptoms in inactive IBD is of utmost importance to ensure unnecessary and potentially 
harmful treatment strategies are avoided, conversely presence of active IBD lesions should be 
excluded before determining that symptoms are functional in nature. 
 Similar treatment strategies as those used in irritable bowel syndrome (IBS) such as 
antispasmodics, antidiarrhoeals and low dose antidepressants can be used for functional bowel 
symptoms in IBD, however there is limited research on their safety and effectiveness in IBD. 
From a dietary perspective, identification of dietary triggers can be helpful 179 but is difficult to 
determine the culprits due to the complexity of the diet and delay of symptom generation 
following consumption of the food or ingredient. In IBS, alteration of dietary fibre intake can be 
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beneficial 180,181; however, there is limited research for functional bowel symptoms in IBD. A 
low (FODMAP) diet is recognized as a successful management strategy for functional bowel 
disorders like IBS 180,182. FODMAPs are poorly absorbed carbohydrates that can increase small 
intestinal luminal water and colonic fermentation by the gastrointestinal microbiota 183-185 which, 
in susceptible individuals, induces functional bowel symptoms 182. Some FODMAPs are 
prebiotic (e.g. fructo-oligosaccharides and galacto-oligosaccharides presumably having a 
beneficial effect on the gastrointestinal microbiota. In IBS, short-term FODMAP reduction 
correlates with reduced luminal Bifidobacterium spp. and F. prausnitzii 186,187 which may 
negatively impact the gastrointestinal microbiome. For this reason, the low FODMAP diet 
incorporates short-term FODMAP restriction (4-8 weeks) to induce symptom control, followed 
by FODMAP reintroduction using food challenges to personal tolerance. Thus, in the long-term, 
only high FODMAP foods that trigger symptoms are avoided maintaining long-term 
nutritionally adequacy 188. Whether the gastrointestinal microbial changes seen following 
FODMAP restriction return to normal in the long term is unknown.  
 In active Crohn’s disease, a RCT of FOS supplementation significantly increased the 
incidence and severity of abdominal symptoms compared to placebo, although it was not known 
if any of these patients had concomitant IBS 189. A double-blind crossover, re-challenge RCT in 
patients with inactive IBD and functional bowel symptoms who had responded to a low 
FODMAP diet showed that FOS, but not GOS or the polyol sorbitol, induced symptoms 190.  
 In a retrospective case-note review of 72 IBD patients (CD=52) who had previously 
received low FODMAP dietary advice, 56% reported overall symptom improvement 121. A 
prospective study of the low FODMAP diet in 88 IBD patients (CD=39) showed significantly 
more patients reported satisfactory relief from their functional bowel symptoms at follow-up 
(78%) compared to baseline (16%; p<0.001) 191. Abdominal pain, bloating, flatulence, belching, 
incomplete evacuation, nausea and heartburn also improved. Similar findings were reported 
when Crohn’s and ulcerative colitis were sub-analysed. In a non-blinded RCT in patients with 
inactive IBD and functional bowel symptoms greater symptom (p=0.02)  and QOL (p<0.001) 
improvements were reported for the low FODMAP diet (n=44) versus habitual diet (n=45) 192.  
Research gaps 
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 Mechanisms of food-related functional symptoms in IBD need to be identified 
 Functional symptoms should be assessed after excluding inflammation, food intolerance, 
coeliac disease etc. 
 Studies are needed to demonstrate whether dietary interventions are effective and safe for 
the management of functional symptoms in patients with inactive IBD. 
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Conclusions  
Hereby, we provide a summary of our current knowledge and emerging evidence on the broad 
role of diet and nutrition in the aetiology and management of IBD. The subject is topical and 
findings of current and future multidisciplinary research are expected to have major impact on 
understanding the dietary influences of CD onset and improving dietary therapies in all aspects 
of IBD management. We propose a list of research gaps that we anticipate to set the future 
research agenda in the topic of nutrition and diet in IBD.      
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Supplementary Figures Legend 
Supplementary Figure 1: Non-exclusive listing of diet-microbiome interactions and its impact 
on gut function contributing to health and disease 
Supplementary Figure 2: The multiple presentations and origins of malnutrition in patients 
with IBD (adapted with permission from Wiley 193)   
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Supplementary Table 1 : Randomised controlled trials and notable non-randomised studies investigating the effectiveness of 
partial enteral nutrition (PEN) compared with habitual diet, exclusive enteral nutrition (EEN) or medical therapy in the 
treatment and maintenance of remission in Crohn’s disease 
Study Study design Population Intervention Comparator(s) Outcomes related 
to disease activity 
Lee et al, 
(2015) 
Treatment 
Non-RCT 
Children/adolescents with 
active CD (PCDAI>10)  
90 patients entered, 80 
analysed. 
PEN (semi-
elemental, mean 
53% of total 
energy intake) 
with normal diet 
for 8 weeks 
EEN with whole 
protein formula or 
Anti-TNF therapy 
for 8 weeks 
PEN resulted in 
fewer with clinical 
response (64%) vs 
EEN (88%) vs anti-
TNF (84%) and 
fewer in clinical 
remission (PCDAI 
≤10) (50%) vs EEN 
(76%). Fewer with 
faecal calprotectin 
≤250μg/g in PEN 
(14%) vs EEN 
(45%) vs anti-TNF 
(62%).  
Hanai et al, 
(2012) 
Maintenance 
RCT 
Adults with inactive CD 
(CDAI≤150) 
95 patients entered, 95 
PEN (elemental, 
≥900 kcal/d) 
orally or via NGT 
(i) 6-MP; or  
(ii) No treatment.  
Both with normal 
PEN resulted in 
44% maintaining 
remission compared 
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analysed plus normal diet 
for up to 2 years 
diet for up to 2 
years 
with 57% in 6-MP 
and 21% in control 
at 2 years 
Triantafillidis et 
al, (2010) 
Maintenance 
RCT 
Adults with inactive CD 
(CDAI<150) 
83 patients entered, 66 
analysed 
PEN (polymeric, 
420 kcal/d) orally 
plus normal diet 
for 6 months 
Mesalamine plus 
normal diet for 6 
months 
PEN resulted in no 
difference in relapse 
rates (31%) 
compared with 
mesalamine (40%) 
at 6 months. 
Yamamoto et 
al, (2010) 
Maintenance 
Non-RCT 
Adults with inactive CD 
infliximab-induced 
remission (CDAI<150) 
56 patients entered, 56 
analysed 
PEN (elemental 
approx. 50% of 
energy 
requirements) via 
NGT plus low fat 
diet for 13 months 
Normal diet for 13 
months 
PEN plus low fat 
diet resulted in no 
difference in 
maintenance of 
remission (78% vs 
67%) and no 
difference in CDAI 
compared with 
normal diet at 13 
months 
Yamamoto et 
al, (2007a) 
Maintenance 
Non-RCT 
Adults with inactive CD, 
medically-induced 
remission (CDAI<150) 
PEN (elemental, 
approx. 50% of 
energy 
Normal diet for up 
to 2 years 
PEN plus low fat 
diet resulted in 
lower relapse rates 
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40 patients entered, 40 
analysed 
requirements) via 
NGT plus low fat 
diet for 12 months 
(25% vs 65%), 
lower CDAI and 
lower endoscopic 
inflammation scores 
(1.25 vs 2.0) 
compared with 
normal diet at 12 
months 
Yamamoto et 
al, (2007b) 
Maintenance 
Non-RCT 
Adults with inactive CD 
surgically-induced 
remission (CDAI<150) 
40 patients entered, 40 
analysed 
PEN (elemental 
approx. 50% of 
energy 
requirements) via 
NGT plus low fat 
diet for 12 months 
Normal diet for up 
to 2 years 
PEN plus low fat 
diet resulted in 
lower relapse rates 
(5% vs 35%) and 
lower endoscopic 
recurrence (30% vs 
70%) compared 
with normal diet at 
12 months 
Johnson et al, 
(2006) 
Treatment 
RCT 
Children with active CD 
(PCDAI>10) 
50 entered, 50 analysed. 
PEN (elemental, 
50% energy 
requirements) 
orally or via 
nasogastric tube 
EEN given as 
elemental formula 
(≥100% energy 
requirements) 
orally or via 
PEN resulted in few 
entering remission 
(PCDAI <10) 
(15%) compared 
with EEN (42%) 
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for 6 weeks nasogastric tube 
for 6 weeks 
and smaller 
reduction in PCDAI 
(-13) compared 
with EEN (-26). 
Takagi et al, 
(2006) 
Maintenance 
RCT 
Adults with inactive CD 
recent medically-, EEN or 
surgically-induced 
remission (CDAI<150) 
51 patients entered, 51 
analysed 
PEN (elemental, 
50% of energy 
requirements) 
orally or via NGT 
plus normal diet 
for up to 2 years 
Normal diet for up 
to 2 years 
PEN resulted in 
lower relapse rates 
(35%) compared 
with normal diet 
(64%) 
Verma et al, 
(2000) 
Maintenance 
Non-RCT 
Adults with inactive CD 
(CDAI<150) 
39 patients entered, 39 
analysed 
PEN as elemental 
(35-50% previous 
energy intake) 
plus normal diet 
for up to 12 
months 
Normal diet for up 
to 12 months 
PEN resulted in 
greater maintenance 
of remission (48%) 
compared with 
normal diet (22%) 
at 12 months. 
Wilschanski et 
al, (1996) 
Maintenance 
Retrospective, non-
RCT, comparative 
evaluation 
Children with EEN-
induced remission (PCDAI 
≤20) 
47 patients entered, 47 
analysed. 
PEN (elemental 
/semi-elemental, 
50-60% of energy 
requirements) 
given overnight 4-
5 times/week via 
Normal diet for up 
to 12 months 
PEN resulted in 
reduction in relapse 
(PCDAI >20) at 6 
months (18% vs 
79%) and 12 
months (43% vs 
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NGT plus normal 
diet for up to 12 
months  
79%). 
Harries et al, 
(1983) 
Treatment 
Cross-over RCT 
Adults with CD and 
malnutrition 
Mildly active (mean HBI 
4.2-5.1).  
35 patients entered, 28 
analysed.  
PEN (polymeric, 
mean 550-560 
kcal/d) plus 
normal diet for 2 
months  
Normal diet for 2 
months 
PEN had no impact 
on HBI. No impact 
on ESR, platelet 
count but greater 
reduction in α1 acid 
glycoprotein 
(orosomucoid). 
EEN, exclusive enteral nutrition 
HBI, Harvey Bradshaw Index 
CDAI, Crohn’s disease activity index 
PCDAI, Paediatric Crohn’s disease activity index 
PEN, partial enteral nutrition 
RCT, randomised controlled trial  
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Supplementary Table 2: Studies investigating the efficacy of exclusion diets in CD and UC 
Diet Author & year Methods & patients Outcomes Results 
SCD Obin, 2015  Retrospective, 26 
children (20 CD, 6 UC), 
several patients used the 
diet as maintenance 
therapy and most of 
them were on 
concomitant medication 
including INF, 10 
controls (7 CD, 3 UC) , 
3-48 months 
Clinical outcomes and 
laboratory markers  
In patients with active CD 
PCDAI dropped from 32.8 
±13.2 at baseline to 20.8 ± 
16.6 by 4 ± 2 weeks, and 
to 8.8 ± 8.5 by 6 months. 
The mean Pediatric 
Ulcerative Colitis Activity 
Index (PUCAI) for patients 
with active UC decreased 
from a baseline of 28.3 ± 
10.3 to 20.0 ±17.3 at 4 ±2 
weeks, to 18.3 ± 31.7 at 6 
months. 
SCD Kakodkar, 2015  Case series, 50 patients 
in remission, 36 CD, 9 
UC, 5 ID, 1-216 
months. Patients were 
on medication including 
biologics 
Management of 
symptom 
Improvement in symptoms 
and quality of life 
Crohn's Disease Exclusion Sigall Boneh, 2014   Retrospective, 47 CD Clinical remission at Clinical remission in 70% 
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Diet [CDED] children & adults 
patients, 12 weeks 
week 6, normalization 
of CRP 
patients, no difference 
between adults and 
children, CRP 
normalization in 70%, 
mucosal healing in 
11/15patients  
SCD Cohen, 2014  Prospective, 10 CD 
patients, 52 weeks 
Clinical and mucosal 
response  
Significant improvement in 
PCDAI and HBI after 12 
and 52 weeks. Lewis 
scores decreased 
significantly after 12 but 
not 52 weeks. 3 patients 
with normal Lewis scores. 
SCD Suskind, 2014  Case series, 7 CD 
children, 5-30 months 
Symptoms and 
laboratory markers 
All symptoms resolved at a 
routine clinic visit 3 
months after treatment 
initiation and during the 
follow up period. 
Improvement in 
abbreviated PCDAI and 
CRP normalized in 5/7 
patients. 
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SCD vs Low residue diet  Walters, 2014  Pilot, Randomized cross 
sectional prospective 
study, 8 patients in 
remission (6 CD, 2 
controls), 30 days- 30 
days washout-30 days  
Comparing the effect 
of diets on the 
microbiome, 
management symptoms 
The SCD was associated 
with increased diversity; 
reduced symptoms 
following SCD compared 
with a Low residue diet 
that demonstrated decrease 
in diversity 
IBD- Anti-inflammatory 
diet 
Olendzki, 2014  Case series, 11patients 
(8 CD, 3 UC), 4 weeks 
Disease activity  All patients discontinued at 
least one of their 
medications. All patients 
had symptom reduction 
including bowel frequency. 
The mean baseline HBI 
was 11 (range 1–20) and 
after 4 weeks was 1.5 
(range 0–3). The mean 
baseline Modified 
Truelove and Witts 
Severity Index (MTLWSI) 
was 7 (range 6–8), and the 
0 after 4 weeks.  
Mediterranean-inspired Marlow, 2013  Prospective, 8 CD Reduction of blood Effect on gene expression 
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diet patients, 6 weeks inflammatory markers and 'normalization' of the 
microbiome, no effect on 
inflammatory markers 
Semi-vegetarian diet 
 
Chiba, 2010 Prospective, 22 CD 
patients in remission 
after medical therapy 
with anti TNF or 
surgery 
16 followed the Semi-
vegetarian diet, 6 were 
controls, 2 years 
Relapse prevention  15/16 (94%) maintained 
remission compared to 2/6 
(33%) in the omnivorous 
group. CRP levels stayed 
normal in 7/10 (70%) who 
completed 2 years follow-
up and were in remission 
Semi-vegetarian diet 
showed significant 
prevention in the time to 
relapse compared with the 
omnivorous group (P = 
0.0003) 
 
FODMAP Gearry, 2008  Retrospective, 72 
patients (52 CD, 20 
UC), 3-6 months 
Management of 
functional symptoms 
Abdominal symptoms, 
abdominal pain, bloating, 
wind and diarrhea 
improved in patients with 
CD and UC (P<0.02 for 
all), constipation did not. 
FODMAP Croagh, 2007  Retrospective and Management of Reduction in the intake of 
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Prospective, 15 patients 
[13 pouch, 2 ileorectal 
anastomosis (IRA)] 
functional symptoms FODMAPs may be 
efficacious in reducing 
stool frequency in patients 
without 
pouchitis 
Exclusion Diet in UC Candy,1995  Prospective RCT, 18 
patients (11 diet, 7 
controls), 6 weeks  
Remission, 
improvement in 
symptoms after 6 
weeks of exclusion diet 
Significantly fewer 
symptoms in diet 
compared to controls 
Improvement in 
sigmoidoscopic and 
histological findings 
4/11 in remission 
Unrefined carbohydrate, 
fiber rich diet 
Ritchie, 1987  Prospective, RCT, 352 
patients (inactive or 
mild CD) 162 patients 
were on unrestricted 
sugar and low in fibre 
diet and 190 were on 
diet with little or no 
sugar and high in 
unrefined carbohydrate. 
Disease activity  in 2 
years 
 
No clear difference in 
clinical course was 
detected among patients 
who followed the two 
different types of dietary 
advice. 
CD- Crohn’s Disease    UC- Ulcerative Colitis  
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HBI- Harvey-Bradshaw Index 
PCDAI- Pediatric Crohn's Disease Activity Index 
SCD -Specific Carbohydrate Diet  
FODMAP- Fermentable Oligo-saccharides, Di-saccharides, Mono-saccharides And Polyols diet 
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